

Treating Opioid Use Disorder Where It's At: Working with Criminal Justice Populations

Timothy P. Condon, Ph.D.

Research Professor

Center on Alcoholism, Substance Abuse and Addictions

University of New Mexico

***NM Legislative Health and Human Services and the Courts,
Corrections and Justice Committees***

Albuquerque, NM

October 9, 2019

Presenter Disclosures

*Chief Science Advisor, Center for Health and Justice at TASC-IL
(Trainer)*

Faculty, National Judicial College


Bernalillo County Opioid Accountability Initiative

Santa Fe Municipal Drug Task Force

Free study medication from Alkermes

Total adult correctional population, 1980–2016


Number



Source: Bureau of Justice Statistics, Annual Survey of Jails, Annual Survey of Parole, Annual Survey of Probation, Census of Jail Inmates, and National Prisoner Statistics, 1980–2016.


How many people are locked up in the United States?

The U.S. locks up more people per capita than any other nation, at the staggering rate of 698 per 100,000 residents. But to end mass incarceration, we must first consider *where* and *why* 2.3 million people are confined nationwide.




How many New Mexico residents are locked up and where?

18,000 of New Mexico's residents are locked up in various kinds of facilities




Regular Drug Abuse



Bureau of Justice Statistics

Cost of Drug Abuse



ONDCP

TCU
© 2014

Recidivism and Relapse

Criminal Recidivism in 3 Years

68% Re-arrested

47% Convicted


50% Re-incarcerated



Relapse to Drug Abuse in 3 Years

95% Relapse


***We Have a Variety of Effective
Treatment Options in the
Clinical Toolbox***



***Medication-assisted treatment (Mostly for Opioid use disorder)
Behavioral and Psychosocial Treatments***

What are relapse rates for drug addiction?


Relapse Rates are Similar to Other Chronic Medical Conditions



Source: McLellan, A.T. et al., JAMA, Vol 284(13), October 4, 2000.

A Continuing Care Model

Primary Care



```
graph TD; A[Primary Care] --> B[Specialty Care]; B --> C[Continuing Care];
```


Specialty Care

Continuing Care

***We Need to View and
Treat Addiction as a
Chronic, Often , Relapsing Illness***

Overdose Deaths


Death Among Recent Inmates of the Washington State Corrections Compared to Other State Residents



Binswanger et al. NEJM 2007;356:157-165


People in CJ System with Opioid Use Disorders are Dying

Mortality rate, by week since release, for overdose and all other (non-overdose) causes of death.



What is drug treatment?

A Chronic Care Approach to Drug Treatment



Detox is NOT Treatment
It can be a part of treatment

Types of Opioid Treatment Medications


Opioid Agonists

- 1) Full agonist: Methadone (oral)
- 2) Partial agonist: Buprenorphine (sublingual, implant & injectable extended release)

Opioid Antagonist

- 3) Naltrexone (oral)
- 4) Extended-release Naltrexone (injection)

What is the Difference between Opioid Agonists & Antagonists?



FDA-approved Medications for Opioid Dependence

- Methadone
- Buprenorphine (Subutex and generics)
- Buprenorphine/Naloxone (Suboxone and generics)
- Oral Naltrexone
- Extended-release Naltrexone-Vivitrol (relapse prevention)
- Probuphine (long acting implants buprenorphine)
- Sublocade (long acting buprenorphine injections)
- Brixadi/Buvidal (long acting buprenorphine injection)
- On the horizon? Extended-release methadone

What is the Difference Between Opioid Addiction and Opioid Agonist Treatment?

| | Opioid Addiction | Agonist Treatment |
|------------------|--------------------------|-------------------------------|
| Route | IV Injected/snorted/oral | Sublingual/oral/ SC injection |
| Euphoria | Yes | Rarely |
| Cost | High | Low |
| Duration | 4 hours | 24 hours (or 30 days) |
| Legal | No | Yes |
| Lifestyle | Chaotic | Normal |

Peer Reviewed Publications by Medication (1960-present)


| MEDICATION | PEER REVIEWED PUBLICATIONS |
|---|----------------------------|
| Methadone | 14,930 |
| Buprenorphine | 6,105 |
| Naltrexone | 9,075 |
| Vivitrol (Extended-release naltrexone) | 260 |
| Probuphine | 38 |
| <i>Sublocade</i> | 6 |

NCBI: Pub Med., US National Library of Medicine National Institute of Health (n.d.).
Retrieved from [PubMedhttps://www.ncbi.nlm.nih.gov/pubmed/](https://www.ncbi.nlm.nih.gov/pubmed/)

Methadone Clinic (dispensing)




Suboxone Film



Probuphine implant

Subdermal Buprenorphine Implant

- Trade name - Probuphine
- Manufactured by Titan Pharma
- Small, solid "rod" (26 mm × 2.5 mm)
- Made from a mixture of ethylene vinyl acetate
- Contains about 80 mg Buprenorphine
- Buprenorphine released over 6 months
- Benefits
 - Decreased risk of diversion and accidental pediatric exposure
 - Improved adherence, convenience



Presented at the national CME "OST: Policy and Practice" on 18th-19th April 2015 at AIIMS, New Delhi

Vivitrol Pack



Recidivism and Relapse

Criminal Recidivism in 3 Years

68% Re-arrested

47% Convicted

50% Re-incarcerated



Relapse to Drug Abuse in 3 Years

95% Relapse

***And these advances have
the potential to help
improve both the***



CRIMINAL JUSTICE

and

HEALTH

***Approaches to Addressing
Drug Abuse and Addiction***

What has been the traditional approaches?


Public Health Approach
-social problem
-disorder or disease
-treatment

High Attrition

Public Safety Approach
-illegal behavior
-punish

High Recidivism

How can drug treatment and criminal justice work together?



Community-Based Methadone Maintenance in a Large Detention Center is Associated with Decreases in Inmate Recidivism

Verner S. Westerberg, Ph.D. Barbara S. McCrady, Ph.D. , Mandy Owens, M.S. , Paul Guerin, Ph.D.

Journal of Substance Abuse Treatment 70 (2016) 1–6

MDC





JAIL-BASED MEDICATION-ASSISTED TREATMENT

PROMISING PRACTICES, GUIDELINES,
AND RESOURCES FOR THE FIELD

October 2018

Who has Endorsed MAT in Correctional Settings?


- National Commission on Correctional Health Care
- American Society of Addiction Medicine
- National Governor's Association
- National Association of Counties
- National League of Cities
- President's 2017 Commission on Combating Drug Addiction and the Opioid Crisis
- National Sheriffs Association
- Me

Summary

- Buprenorphine products, methadone and oral and extended-release naltrexone are approved by the FDA as safe and effective for the treatment of opioid dependence and relapse prevention, respectively
- They all reduce the use of illicit opioids and are more effective than no medication ‘drug free’ treatment
- They can be used as tools to improve the public health and the public safety in our communities

People in CJ System with Opioid Use Disorders are Dying

Mortality rate, by week since release, for overdose and all other (non-overdose) causes of death.



In Treating Addiction...

*We Need to Keep Our Eye on
the Real Target*



- *Reduce Crime*
- *Save Money*
- *Improve Lives*



Treatment
is the Key
drugabuse.gov

Thank you



CENTER ON ALCOHOLISM,
SUBSTANCE ABUSE,
& ADDICTIONS

tcondon@unm.edu

Where can intervention/treatment occur in the criminal justice system?

